About Multiple Sclerosis


Multiple sclerosis (MS):

Multiple sclerosis (MS) is an unpredictable, often debilitating disease of the central nervous system (CNS) that disrupts the flow of information within the brain, and between the brain and the body.
About Muptiple Sclerosis

An Uncertain Future


More than 2 million people in the world
400,000 in the US.

MS AffectsMost people diagnosed between the ages of 20 and 50.


Although not fully understood, demyelination of axons in the CNS is caused by the immune system attacking the myelin sheath.

MS Causes

Types of MS and Progression

Relapsing Remitting (RRMS)

Most common

Characterized by clearly defined attacks of new or increasing neurological symptoms called relapses or exacerbations

Relapses can be followed by periods of partial or complete recovery (remissions)

Secondary Progressive (SPMS)

Most people who are diagnosed with RRMS will eventually transition to a secondary progressive course in which there is a progressive worsening of neurologic function (accumulation of disability) over time.

Primary Progressive (PPMS)

Worsening neurologic function (accumulation of disability) from the onset of symptoms, without early relapses or remissions.

Signs and Symptoms

Severity and specific symptoms of MS in any one person cannot yet be predicted.

MS Affects

Vision loss

MS Affects


MS Affects

Impaired cognition

MS Affects

Weakness impaired mobility

Current Therapies

Modulate the immune system to slow disease progression.

Currently there are no therapies that cause remyelination.

MS Affects

of patients diagnosed with RRMS advance to progressive MS within 19 years of diagnosis

Current Therapies


ENDECE has discovered a drug with the ability to induce the process for restoring and repairing the myelin sheath.

NDC 1308

ENDECE Approach To Remyelination

ENDECE has discovered and is developing NDC-1308, a new therapy with a dual mechanism of action (MOA) designed to provide the necessary anti-inflammatory, pro-repair environment at lesions and upregulate genes necessary for inducing OPCs to differentiate into mature oligodendrocytes responsible for remyelination.

For more information go to About NDC-1308


A new drug with a unique dual mechanism of action (MOA) for inducing remyelination, the process for restoring and repairing the myelin sheath in demyelinating diseases including multiple sclerosis, neuromyelitis optica, and osmotic demyelination syndrome.

To request more information go to; ENDECE.com/contact